Semi-Solid Phase Assay for the Alternative Complement Pathway Activity Assessment (AP<sub>100</sub>)
Since the introduction of the most expensive drug in the world (Eculizumab) in the therapeutic arsenal of many diseases involving the alternative complement pathway (ACP) in their pathophysiology, the unmet need to perform simple ACP assays affordable for all countries has become one of the major ch...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2020
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/64152 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares: Semi-Solid Phase Assay for the Alternative Complement Pathway Activity Assessment (AP<sub>100</sub>)
- Effect of M Substitution on Structural, Magnetic and Magnetocaloric Properties of R<sub>2</sub>Fe<sub>17-x</sub> M<sub>x</sub> (R = Gd, Nd; M = Co, Cu) Solid Solutions
- Crystal Structure of [C<sub>17</sub>H<sub>22</sub>N<sub>2</sub>]<sub>3</sub>[P<sub>6</sub>O<sub>18</sub>][H<sub>2</sub>O]<sub>8</sub>
- Structural Phase Transitions of Hybrid Perovskites CH<sub>3</sub>NH<sub>3</sub>PbX<sub>3</sub> (X = Br, Cl) from Synchrotron and Neutron Diffraction Data
- Practical Guide for Causal Pathways and Sub-group Disparity Analysis
- SubApSnap: Solving parameter-dependent linear systems with a snapshot and subsampling
- MoS<sub>2</sub> Exfoliated in Liquid Phase: Size Selection, Networks, and Applications